Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA to Predict Anthracycline-based Neoadjuvant Chemotherapy Response in HER2-negative Breast Cancer
ChiCTR-OPC-17011144Phase 4Not yet recruiting
- Sponsor
- Department of Breast Surgery, the First Affiliated Hospital of Xi’an Jiaotong University
- Start
- Jun 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of epirubicin in breast cancer, sponsored by Department of Breast Surgery, the First Affiliated Hospital of Xi’an Jiaotong University. Primary endpoint: Tumor burden. Planned start Jun 2017; status: not yet recruiting.
02
Drugs
epirubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR-OPC-17011144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17011144.